electroCore (ECOR) Registration Filing summary

Company overview and business model

• Commercial-stage bioelectronic medicine and wellness company focused on non-invasive vagus nerve stimulation (nVNS) technology for health improvement and quality of life enhancement.

• Product portfolio includes prescription medical devices (gammaCore) for primary headache, consumer wellness devices (Truvaga), and human performance solutions (TAC-STIM).

• gammaCore Sapphire is FDA-cleared for primary headache conditions and is available by prescription; Truvaga products are direct-to-consumer and do not require a prescription.

• TAC-STIM is developed in collaboration with the U.S. Department of Defense and is being evaluated by military organizations.

• Entered into a definitive agreement to acquire NeuroMetrix, Inc. (NURO), expanding into chronic pain neuromodulation markets.

Financial performance and metrics

• As of January 14, 2025, 6,656,187 shares of common stock were outstanding.

• The company qualifies as a "smaller reporting company" under SEC rules, allowing for scaled disclosure and reduced compliance requirements.

• The consolidated financial statements for 2023 and 2022 include a going concern explanatory paragraph from the independent auditor.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for sales and marketing, working capital, and general corporate purposes.

• May allocate funds to acquisitions, in-licenses, or investments in complementary companies, medicines, IP, or technologies, including the potential acquisition of NURO.

• Management has broad discretion over the use of proceeds; no specific material uses identified as of the filing date.

• Pending use, proceeds may be invested in interest-bearing, investment-grade instruments or U.S. government obligations.